Literature DB >> 8946430

The D2 receptor occupancy profile of loxapine determined using PET.

S Kapur1, R B Zipursky, C Jones, G J Remington, A A Wilson, J DaSilva, S Houle.   

Abstract

Positron emission tomography (PET) studies of typical neuroleptics suggest that 60% to 80% of striatal D2 occupancy may be sufficient for optimal clinical treatment of psychosis. Therefore, striatal D2 occupancy may be used as an index to determine the optimal dose range. Toward this end, we determined the in vivo D2 profile of loxapine, using [11C]-raclopride and PET. Seven patients selected from a clinical population were scanned while taking steady-state oral loxapine from 10 to 100 mg/day. Their D2 receptor occupancy was estimated by comparing them to age-matched data from neuroleptic-naive patients. The D2 receptor occupancy ranged from 52% to 90%, and there was a very strong relationship between dose and D2 occupancy, suggesting that 15 to 30 mg/day of loxapine would produce, the putatively optimal, 60% to 80% striatal D2 blockade. This dose range is much lower than that used in most clinical settings and points to the potential efficacy of loxapine at lower doses.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8946430     DOI: 10.1016/S0893-133X(96)00100-5

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  9 in total

Review 1.  First- and second-generation antipsychotic medication and cognitive processing in schizophrenia.

Authors:  Thomas W Weickert; Terry E Goldberg
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

2.  Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study.

Authors:  Takefumi Suzuki; Ariel Graff-Guerrero; Hiroyuki Uchida; Gary Remington; Fernando Caravaggio; Carol Borlido; Bruce Pollock; Benoit Mulsant; Vincenzo Deluca; Zahinoor Ismail; David Mamo
Journal:  Psychopharmacology (Berl)       Date:  2013-02-17       Impact factor: 4.530

3.  A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens.

Authors:  Zhu Li; Junji Ichikawa; Herbert Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2003-03-28       Impact factor: 4.530

4.  A positron emission tomography (PET) study of cerebral dopamine D2 and serotonine 5-HT2A receptor occupancy in patients treated with cyamemazine (Tercian).

Authors:  Y Hodé; M Reimold; A Demazières; G Reischl; F Bayle; P Nuss; A Hameg; M Dib; J P Macher
Journal:  Psychopharmacology (Berl)       Date:  2005-03-15       Impact factor: 4.530

Review 5.  Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.

Authors:  O D Howes; A Egerton; V Allan; P McGuire; P Stokes; S Kapur
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

Review 6.  What's in a name? The evolution of the nomenclature of antipsychotic drugs.

Authors:  Caroline King; Lakshmi N P Voruganti
Journal:  J Psychiatry Neurosci       Date:  2002-05       Impact factor: 6.186

Review 7.  Glutamate and dopamine in schizophrenia: an update for the 21st century.

Authors:  Oliver Howes; Rob McCutcheon; James Stone
Journal:  J Psychopharmacol       Date:  2015-01-13       Impact factor: 4.153

8.  Adenosine A2A Receptor Occupancy by Caffeine After Coffee Intake in Parkinson's Disease.

Authors:  Kenji Ishibashi; Yoshiharu Miura; Kei Wagatsuma; Jun Toyohara; Kiichi Ishiwata; Kenji Ishii
Journal:  Mov Disord       Date:  2022-01-09       Impact factor: 9.698

9.  Review of serum prolactin levels as an antipsychotic-response biomarker.

Authors:  Judith M Gault; Abraham M Nussbaum
Journal:  Open Access J Transl Med Res       Date:  2018-05-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.